Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Gastroenterology | Infections and Infectious Diseases | Family Medicine
Disease Category: Irritable Bowel Syndrome (IBS)
Location: United States, CA
Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS) needed for a clinical research trial
A Phase 2, Multicenter, Randomized, Double-Blind,
Placebo-Controlled, Study To Access The Efficacy And Safety Of
Three Different Doses (275, 550, and 1100 MG) Of Rifaximin
Administered BID For Either Two Or Four Weeks in the Treatment of
Patients With Diarrhea-Associated Irritable Bowel Syndrome
Study visits include a screening visit and 8 office visits over
Call today if you would like to learn more about this study and
to find out if you qualify.
CW ID: 84972
Date Last Changed:
July 25, 2013
Silvia Sanchez, Patient Recruitment CoordinatorAnaheim Clinical Trials (ACT)1211 W. La Palma Ave., Suite 602Anaheim, CA 92801Phone: 714-778-1309 x.227Fax: 714-778-0667
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2016 CenterWatch.